⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 29, 2024Open Access

TABLE 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma

Nicholas J. Hornstein Mohammad A. Zeineddine Betul Beyza Gunes Andrew J. Pellatt Mark Knafl Haifeng Zhu Anneleis F. Willett Abdelrahman Yousef Suyu Liu Ryan Sun P. Andrew Futreal Scott E. Woodman Melissa W. Taggart Michael J. Overman Daniel M. Halperin Kanwal Raghav John Paul Shen

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Patient demographics and molecular status

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hornstein et al. (2024) studied this question.

synapsesocial.com/papers/68e67f58b6db64358760858d https://doi.org/10.1158/2767-9764.25922592.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1TABLE 1 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma2024
2Supplemental Figure 2 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma2024
3Supplemental Figure 2 from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma2024
4Data from Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma2024
5Survival Outcomes and Prognostic Factors in Metastatic Unresectable Appendiceal Adenocarcinoma Treated with Palliative Systemic Chemotherapy: A 10-Year Retrospective Analysis from Australia2025